17
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Artificial Intelligence in Gastroenterology

      Submit here before May 31, 2024

      About Digestion: 3.2 Impact Factor I 6.4 CiteScore I 0.914 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Study on Clinical Factors Involved in Helicobacter pylori -Uninfected, Undifferentiated-Type Early Gastric Cancer

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: The factors associated with the pathogenesis of Helicobacter pylori-uninfected undifferentiated-type early gastric cancer (HPUGC) remain unclear. This study compared patient characteristics, including medical history and alcohol/tobacco use, of HPUGC patients with characteristics of patients with H. pylori-positive undifferentiated-type early gastric cancer (HPPGC) to clarify and gain understanding on those differences that could play a role in the pathogenesis. Methods: This retrospective study included 282 patients who were treated endoscopically from March 2005 to March 2014. This cohort consisted of 232 patients with HPPGC (82.3%) and 50 patients with HPUGC (17.7%). Patient characteristics were analyzed by subgroups of HPUGC vs. HPPGC, with comparisons for age, gender, cancer history, comorbidity of lifestyle diseases requiring medication (hypertension, type 2 diabetes, and dyslipidemia), cumulative amount of alcohol consumption, and smoking history (Brinkman index [BI]). Results: HPUGC patients were typically younger, had less frequent hypertension, and had higher BI values ( p < 0.05 for all parameters). In a younger non-hypertensive subgroup, the OR for high BI (BI ≥340) in the HPUGC group vs. HPPGC group was 5.049 (95% CI 2.458–10.373, p < 0.0001). Conclusions: The investigation of clinical factors identified smoking history as being possibly contributing to the pathogenesis of HPUGC. Future research is necessary at the cellular and genetic levels.

          Related collections

          Author and article information

          Journal
          DIG
          Digestion
          10.1159/issn.0012-2823
          Digestion
          S. Karger AG
          0012-2823
          1421-9867
          2017
          November 2017
          19 October 2017
          : 96
          : 4
          : 213-219
          Affiliations
          [_a] aDepartment of Gastroenterology, Cancer Institute Hospital, Tokyo, Japan
          [_b] bDepartment of Clinical Trial Planning and Management, Cancer Institute Hospital, Tokyo, Japan
          [_c] cDepartment of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan
          Author notes
          *Yusuke Horiuchi, Department of Gastroenterology, Cancer Institute Hospital, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550 (Japan), E-Mail yusuke.horiuchi@jfcr.or.jp
          Article
          481817 Digestion 2017;96:213–219
          10.1159/000481817
          29050004
          5130c325-d768-441a-a18f-d9f629895107
          © 2017 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 20 July 2017
          : 27 September 2017
          Page count
          Figures: 2, Tables: 4, Pages: 7
          Categories
          Original Paper

          Oncology & Radiotherapy,Gastroenterology & Hepatology,Surgery,Nutrition & Dietetics,Internal medicine
          Helicobacter pylori ,Gastrointestinal cancer,Smoking,Stomach,Gastric cancer

          Comments

          Comment on this article